Trial Profile

A study evaluating combinations of FPI-2265 and Olaparib

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 21 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Actinium 225 PSMA imaging and therapy (Primary) ; Olaparib (Primary)
Indications Prostate cancer
Focus Therapeutic Use

Most Recent Events

07 May 2024 According to Fusion Pharmaceuticals media release, company expects to initiate a combination trial in the second quarter of 2024.
15 Jan 2024 New trial record
04 Jan 2024 According to Fusion Pharmaceuticals media release, the company expects to initiate this trial in the first half of this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com